| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Molecular Biology and Genetics |
Samuel Lunenfeld Research Institute [V. V., A. M., L. B., B. B.] and Department of Pathology and Laboratory Medicine, Mount Sinai Hospital [V. V., A. M., B. B.], Toronto, Ontario, M5G 1X5 Canada; University Health Network, The Princess Margaret Hospital [W. C.], Toronto, Ontario, M5G 2C4 Canada; and Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, M5G 1L5 Canada [V. V., A. M., W. C., B. B.]
Microsatellite instability (MSI) is observed in a subset of endometrial cancers (ECs) and is attributed to defects in mismatch repair. Mismatch repair deficiency allows for accumulation of mutations in the coding repeats of key target genes, which may be involved in the initiation and progression of MSI+ EC. We examined genes implicated in DNA repair pathways in 38 MSI-high (MSI-H), 10 MSI-low, 25 microsatellite stable ECs, and a selected panel of associated premalignant hyperplasias. Genetic alterations were correlated to histopathological data, including tumor grade and stage. Somatic frameshift mutations were observed in hMLH3, hMSH3, hMSH6, CHK1, and BAX genes in MSI-H endometrial hyperplasias and cancers, whereas mutations in ATR and CDC25C were observed only in MSI-H ECs. Increased mutation frequency in DNA damage response pathway genes including ATR, CHK1, and BAX demonstrated a significant trend with advancing tumor grade (P < 0.05). Our observations of the same mutations at short coding mononucleotide repeats in both premalignant lesions and tumors and association of increased frequency of mutation accumulation with advancing tumor grade suggest that these alterations may play a role in the development and progression of MSI+ EC.
This article has been cited by other articles:
![]() |
I. Zighelboim, A. P. Schmidt, F. Gao, P. H. Thaker, M. A. Powell, J. S. Rader, R. K. Gibb, D. G. Mutch, and P. J. Goodfellow ATR Mutation in Endometrioid Endometrial Cancer Is Associated With Poor Clinical Outcomes J. Clin. Oncol., July 1, 2009; 27(19): 3091 - 3096. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. D. Kauff ATR Mutations in Endometrial Cancer: A Window Into the Role of Mismatch Repair Defects J. Clin. Oncol., July 1, 2009; 27(19): 3077 - 3078. [Full Text] [PDF] |
||||
![]() |
K. A. Lewis, K. K. Lilly, E. A. Reynolds, W. P. Sullivan, S. H. Kaufmann, and W. A. Cliby Ataxia telangiectasia and rad3-related kinase contributes to cell cycle arrest and survival after cisplatin but not oxaliplatin Mol. Cancer Ther., April 1, 2009; 8(4): 855 - 863. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Aishwarya and P. C. Sharma UgMicroSatdb: database for mining microsatellites from unigenes Nucleic Acids Res., January 11, 2008; 36(suppl_1): D53 - D56. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. S. Levitt, M. Zhu, A. Cassano, S. A. Yazinski, H. Liu, J. Darfler, R. M. Peters, and R. S. Weiss Genome Maintenance Defects in Cultured Cells and Mice following Partial Inactivation of the Essential Cell Cycle Checkpoint Gene Hus1 Mol. Cell. Biol., March 15, 2007; 27(6): 2189 - 2201. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Zaugg, Y.-W. Su, P. T. Reilly, Y. Moolani, C. C. Cheung, R. Hakem, A. Hirao, Q. Liu, S. J. Elledge, and T. W. Mak Cross-talk between Chk1 and Chk2 in double-mutant thymocytes PNAS, March 6, 2007; 104(10): 3805 - 3810. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. P. Taylor, M. A. Powell, R. K. Gibb, J. S. Rader, P. C. Huettner, S. N. Thibodeau, D. G. Mutch, and P. J. Goodfellow MLH3 Mutation in Endometrial Cancer. Cancer Res., August 1, 2006; 66(15): 7502 - 7508. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. O'Brien and R. Brown Signalling cell cycle arrest and cell death through the MMR System Carcinogenesis, April 1, 2006; 27(4): 682 - 692. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. A. Freiberg, E. M. Hammond, M. J. Dorie, S. M. Welford, and A. J. Giaccia DNA Damage during Reoxygenation Elicits a Chk2-Dependent Checkpoint Response. Mol. Cell. Biol., March 1, 2006; 26(5): 1598 - 1609. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. R. Payne and C. J. Kemp Tumor suppressor genetics Carcinogenesis, December 1, 2005; 26(12): 2031 - 2045. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Lewis, S. Mullany, B. Thomas, J. Chien, R. Loewen, V. Shridhar, and W. A. Cliby Heterozygous ATR Mutations in Mismatch Repair-Deficient Cancer Cells Have Functional Significance Cancer Res., August 15, 2005; 65(16): 7091 - 7095. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Marinkovic, T. Marinkovic, E. Kokai, T. Barth, P. Moller, and T. Wirth Identification of novel Myc target genes with a potential role in lymphomagenesis Nucleic Acids Res., October 11, 2004; 32(18): 5368 - 5378. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y.-C. Li, A. B. Korol, T. Fahima, and E. Nevo Microsatellites Within Genes: Structure, Function, and Evolution Mol. Biol. Evol., June 1, 2004; 21(6): 991 - 1007. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Kawabe G2 checkpoint abrogators as anticancer drugs Mol. Cancer Ther., April 1, 2004; 3(4): 513 - 519. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Reese, L. Liu, and S. L. Gerson Repopulating defect of mismatch repair-deficient hematopoietic stem cells Blood, September 1, 2003; 102(5): 1626 - 1633. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |